Fig. 1From: Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patientsCo-primary endpoints at month 3 for integrated Elaris EM-I and Elaris EM-II by baseline demographic subgroups. A Dysmenorrhea responders. B Non-menstrual pelvic pain responders. Ratios equal the number of responders over the total number of women in each treatment group per subgroup. Green indicates placebo, purple indicates elagolix 150Â mg QD and orange indicates elagolix 200Â mg BID. BID twice daily; BMI body mass index; QD once dailyBack to article page